Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (2)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
Thailand (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
Wolfgang Ollig to become new CFO of the STADA Group
- 29/01/2020
- Press Release
- Wolfgang Ollig to succeed Mark Keatley on 1 February 2020.
- Wolfgang has more than 15 years of experience as Group CFO in a variety of industries including medical and automotive.
- STADA CEO Peter Goldschmidt said: “Wolfgang’s deep knowledge in managing all financial aspects of a global company with broad portfolios as well as his passion and strong credibility will help to accelerate STADA’s ongoing growth journey.”
Bad Vilbel, January 29, 2020 – The Supervisory Board of STADA Arzneimittel AG has appointed Wolfgang Ollig to become Group CFO with effect from 1 February 2020. He succeeds Mark Keatley who joined STADA in 2017. Mark Keatley has decided to step down as CFO for personal reasons.
Wolfgang Ollig, who received his PhD summa cum laude in Business Administration from the University of Regensburg, has more than 15 years of Group CFO experience in various industries including medical and automotive. He also worked for several years at McKinsey, serving global industry clients. Most recently, Wolfgang Ollig worked for WSA, A.S. Denmark, based in Singapore. WSA, A.S. Denmark is a leader in hearing aid manufacturing, with over 10,000 employees.
Prior to this, Wolfgang Ollig spent 10 years as Group CFO at Hella KGaA Hueck & Co. In this role he supported the strong business and profitability growth and was instrumental in the listing of the business on the German Stock Exchange in 2014.
“Wolfgang’s deep knowledge in managing all financial aspects of a global company with broad portfolios, as well as his passion and strong credibility, will help to accelerate STADA’s ongoing growth journey,” says STADA CEO Peter Goldschmidt.
“I would also like to use this opportunity to express my sincere thanks to Mark Keatley. For more than two years, he has played a leading role in initiating and implementing the transformation of the company in order to improve efficiency and productivity. I also want to thank Mark for his professional handover to Wolfgang,” adds Peter Goldschmidt.
At STADA, Wolfgang Ollig will be a crucial part of the company’s growth journey to ensure that STADA lives up to its vision to be the partner of choice in generics as well as in consumer health and to outperform the industry in terms of growth and profitability. He states: “I am really looking forward to joining the team and contributing to making STADA the leading company in the industry”.
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.
Additional information for journalists
STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de
Additional information for capital market participants
STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de
-
Download in PDF format
- Share